Peptide Drug Conjugates Development Service
Welcome to Alfa Cytology's Peptide Design and Synthesis Services, dedicated to revolutionizing cancer therapy through innovative peptide-based treatments. Our cutting-edge services are tailored to meet the unique challenges of cancer treatment, offering customized peptide design and synthesis solutions to target specific tumor biomarkers and signaling pathways. With a commitment to excellence and a focus on precision medicine, we aim to empower researchers and clinicians with advanced peptide therapeutics that hold the promise of improved patient outcomes in the fight against cancer.
Introduction to Peptide Drug Conjugates
Peptide Drug Conjugates represent a groundbreaking approach in cancer therapy, combining the selectivity of peptides with the cytotoxic potency of small-molecule drugs. At Alfa Cytology, our peptide drug conjugates development service aims to overcome the limitations of conventional chemotherapy by precisely delivering therapeutic payloads to cancer cells while sparing healthy tissues. Through strategic conjugation strategies and innovative drug delivery systems, we seek to maximize therapeutic efficacy and minimize adverse effects, ushering in a new era of targeted cancer treatment.
Fig.1 Peptide-Drug Conjugates. (Alas, M., et al., 2021)
Common functional groups in the linker region can be broadly classified into four groups: enzyme-cleavable (esters, amides, and carbamates), acid-cleavable (hydrazones and carbonates), reducible disulfides, and non-cleavable (thioethers, oximes, and triazoles). The classification is based on how these functional groups behave after cellular uptake or under in vivo conditions. Linkage group chemistry plays an important role in the success of PDCs in improving efficacy.
Linker Chemistries of the ADCs Approved for Therapeutic Use
| ADC |
Linker Chemistry |
Year approved |
| Enzyme cleavable |
| Brentuximab vedotin (Adcetris) |
carbamate, dipeptide, thioether |
2011 |
| Polatuzumab vedotin (Polivy) |
carbamate, dipeptide, thioether |
2019 |
| Enfortumab vedotin (Padcev) |
carbamate, dipeptide, thioether |
2019 |
| Trastuzumab deruxtecan (Enhertu) |
amide, tripeptide, thioether |
2019 |
| Trastuzumab emtansine (Kadcyla) |
thioether, amide |
2013 |
| Enzyme or acid cleavable/ Reducible disulfide |
| Gemtuzumab ozogamicin (Mylotarg) |
disulfide, hydrazone, amide |
2000* |
| Inotuzumab ozogamicin (Besponza) |
disulfide, hydrazone, amide |
2017 |
| Acid cleavable |
| Sacituzumab govitecan (Trodelvy) |
carbonate, triazole, thioether |
2020 |
Our Services
Our peptide drug conjugates development service combines peptides with therapeutic agents to create targeted cancer treatments, improving precision and minimizing side effects.
Targeted Drug Delivery Systems
- Design and synthesis of peptide-based carriers capable of selectively delivering cytotoxic drugs to cancer cells while minimizing off-target effects.
- Optimization of drug loading capacity, stability, and release kinetics to enhance therapeutic efficacy and minimize systemic toxicity.
Conjugation Chemistry
- Development of site-specific conjugation methods for linking peptides with cytotoxic drugs, ensuring precise control over drug loading and release.
- Selection of linker molecules and attachment chemistries tailored to optimize stability, specificity, and pharmacokinetic properties of PDCs.
Biological Evaluation
- In vitro and in vivo assessment of PDCs to evaluate their cytotoxicity, selectivity, pharmacokinetics, and therapeutic potential.
- Validation of PDC efficacy in relevant preclinical cancer models, including xenograft studies and patient-derived tumor models.
Advantages of Our Service
- Precision Targeting: Peptide Drug Conjugates enable precise targeting of cancer cells through selective recognition of tumor-specific biomarkers, minimizing off-target effects on healthy tissues.
- Enhanced Therapeutic Index: By delivering cytotoxic drugs directly to cancer cells, PDCs offer the potential to achieve higher therapeutic concentrations within tumors while reducing systemic exposure and associated toxicity.
- Customized Solutions: Our tailored approach allows for the design and optimization of PDCs tailored to the unique characteristics of each cancer type, enabling personalized treatment strategies for improved patient outcomes.
- Multidisciplinary Expertise: Access to a team of experienced scientists and researchers specialized in peptide chemistry, drug conjugation, and cancer biology, offering comprehensive support and guidance throughout the development process.
Choose Alfa Cytology for peptide drug conjugates development service, and embark on a journey towards innovative cancer therapy solutions that prioritize precision, efficacy, and patient-centered care. Contact us today, and get started with out innovative service.
Reference
-
Alas, M., et al.; (2020). Peptide–drug conjugates with different linkers for cancer therapy. Journal of medicinal chemistry, 64(1), 216-232.
For research use only.
Related Services
